Catalysts for Cipla Ltd
17 tracked
Apr 6, 2026
approval
DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (DAPAGLIFLOZIN) — FDA approval
DAPAGLIFLOZIN
→
Apr 6, 2026
approval
DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (DAPAGLIFLOZIN) — FDA approval
DAPAGLIFLOZIN
→
Apr 6, 2026
approval
DAPAGLIFLOZIN — FDA approval
DAPAGLIFLOZIN
→
Apr 2, 2026
approval
NINTEDANIB ESYLATE — FDA approval
Ofev
→
Feb 2, 2026
approval
LENALIDOMIDE — FDA approval
LENALIDOMIDE
→
Jan 30, 2026
approval
EPIRUBICIN HYDROCHLORIDE — FDA approval
EPIRUBICIN HYDROCHLORIDE
→
Dec 10, 2025
recall
Cipla Limited recall (Cls II)
Cipla Ltd
→
Nov 21, 2025
approval
ALBUTEROL SULFATE — FDA approval
ALBUTEROL SULFATE
→
Oct 28, 2021
approval
ALBUTEROL SULFATE — FDA approval
ALBUTEROL SULFATE
→
Nov 4, 2020
approval
ALBUTEROL SULFATE — FDA approval
ALBUTEROL SULFATE
→
Apr 8, 2020
approval
ALBUTEROL SULFATE — FDA approval
ALBUTEROL SULFATE
→
Jan 27, 2020
approval
EPIRUBICIN HYDROCHLORIDE — FDA approval
EPIRUBICIN HYDROCHLORIDE
→
Jan 27, 2020
approval
EPIRUBICIN HYDROCHLORIDE — FDA approval
EPIRUBICIN HYDROCHLORIDE
→
Dec 20, 2014
approval
EPIRUBICIN HYDROCHLORIDE — FDA approval
EPIRUBICIN HYDROCHLORIDE
→
Dec 20, 2014
approval
EPIRUBICIN HYDROCHLORIDE — FDA approval
EPIRUBICIN HYDROCHLORIDE
→
Dec 20, 2014
approval
EPIRUBICIN HYDROCHLORIDE — FDA approval
EPIRUBICIN HYDROCHLORIDE
→
Oct 22, 2007
approval
EPIRUBICIN HYDROCHLORIDE — FDA approval
EPIRUBICIN HYDROCHLORIDE
→